UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
2.
Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280:1490-1496.
3.
American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care. 2004;27(suppl 1):S1-S150.
4.
American Association of Clinical Endocrinologists and American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management—2002 update. Endocr Pract. 2002;8(suppl 1):41-82.
5.
Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes: application, benefits, and risks. Diabetes Rev. 1995;3:308-334.
6.
The DAWN (Diabetes Attitudes, Wishes and Needs) Study. Practical Diabetes Intl. 2002;19:22a-24a.
7.
Fitzgerald JT, Vijan S, Stuart NS. Insulin therapy and patient attitudes at two VA centers [abstract 1886-PO]. Diabetes. 2000;49(suppl 1):A445.
8.
Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients’ fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care. 1997;20:292-298.
9.
Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46:239-246.
10.
Korbel G, Korytkowski M. Insulin therapy resistance. Practical Diabetol. 2003;22:36-40.
11.
Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes Related Metab Disord. 2002;26(suppl 13): S25-S30.
12.
Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2001;109(suppl 2): S317-S332.
13.
Spollett GR. Basal-bolus insulin therapy. Practical Diabetol. 2003;21:33-36.
14.
Fritsche A, Schweitzer MA, Häring H-U, and the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2003;138:952-959.
15.
Rosenstock J, Riddle MC, for the HOE 901/4002 Study Group. Treatment to target study: timing and frequency of nocturnal hypoglycemia. The value of adding bedtime basal insulin glargine over NPH insulin in insulin-naive patients with type 2 diabetes on oral agents [abstract 1982-PO]. Diabetes. 2002;51(suppl 2):A482.
16.
Wolpert HA, Anderson BJ. Management of diabetes: are doctors framing the benefits from the wrong perspective?BMJ. 2001;323:994-996.
17.
Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Related Metab Disord. 2002;26(suppl 3): S18-S24.
18.
Rubin RR, Peyrot M. Psychological issues and treatments for people with diabetes. J Clin Psychol. 2001;57:457-478.
19.
Leslie CA, Satin-Rappaport W, Matheson D, Stone R, Enfield G. Psychological insulin resistance: a missed diagnosis?Diabetes Spectrum. 1994;7:52-57.
20.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22:1125-1136.
21.
Pibernik-Okanovic M, Szabo S, Metelko Z. Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics. 1998;14:201-207.
22.
Van der Does FE, de Neeling JND, Snoek FJ, et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care. 1996;19:204-210.
23.
Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25:1159-1171.
24.
Snoek FJ. Psychological insulin resistance: patient or provider?Diabetes Voice. 2001;46:26-28.
